About Us

We organize 3000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums on various topics of Science & Technology across the globe with support from 1000 more scientific societies and Publishes 500+ Open Access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

The organization feels proud and honoured in inviting the contributors across the globe to its premier World Summit on Nosocomial and Healthcare associated Infections to be held during December 02-03,at New York, USA.

sessions/Tracks

Track 1: Hospital Infections

Hospital infections are one of the major complications for health care  professionals to tackle. Every day they results in prolonged hospital stays, long-term disability, and increased resistance of microbes to antimicrobials, additional costs for healthcare systems, high costs for patients and their family, and unnecessary deaths.
 

Track 2: Device-Related Infections

Medical devices are responsible for a large proportion of nosocomial infections, mainly in critically ill patients. The infections associated with the devices can cause significant medical and economic sequela. The bacterial colonization of the indwelling device may be a prelude to both the infection and the malfunction of the device. The pathogenesis of the infections associated with the devices is centred on the multifaceted interaction of microbial, device and hosts factors.
 

Track 3: Surgical Site Infections

Surgical site Infection is a type of infection associated with healthcare in which a wound infection occurs after an invasive (surgical) procedure. They have a significant effect on the quality of life of the patient and are associated with significant morbidity and prolonged hospital stay. Further these infections result in considerable financial burden for health care providers.
 

Track 4: Urinary Tract Infections

A urinary tract infection is an infection relating to any part of the urinary system, including the urethra, bladder, ureters and kidneys. It is the most common type of hospital infection, among which urinary catheter infection is more frequent and caused by the urinary catheter, which is a tube inserted into the bladder through the urethra to drain the urine.
 

Track 5: Respiratory disorders and infections

Pneumonia contracted by a patient in a hospital at least 48-72 hours after admission is known as Nosocomial pneumonia and Pneumonia associated with health risk factors such as prior hospitalization, dialysis, residing in a nursing home, immunocompromised condition is classified as a health care-associated pneumonia.
 

Track 6: Blood Stream Infections

Blood Infections or Bacteraemia or Sepsis occurs when a bacterial infection occur somewhere else in the body such as in the lungs or skin which enters the blood stream. This is dangerous because bacteria and their toxins can be transported through the bloodstream to the entire body.

Track 7: Microbial Biofilms

Microbial biofilms develop when microorganisms irreversibly adhere to a submerged surface and produce extracellular polymers that facilitate adhesion and provide a structural matrix. The Surface may be an inert, non-living or living tissue. Microorganisms may originate from the skin of patients or health workers, from tap water to which ports of entry are exposed, or from other sources in the environment. To better understand and control biofilms on permanent medical devices, researchers must develop reliable sampling and measurement techniques, study the role of biofilms in antimicrobial resistance, and to establish the link between biofilm contamination and infection of the patient.

Track 8: Emerging Infectious Diseases

Emerging infectious diseases are caused by newly recognized species or strains (such as Severe Acute Respiratory Syndrome, HIV / AIDS) that may have evolved from a known infection (such as influenza) or spread to a new population (Such as West Nile fever) or undergoing ecological transformation (such as Lyme disease) or re-emerging infections, such as drug-resistant tuberculosis. Nosocomial infections caused by methicillin-resistant Staphylococcus aureus are emerging in hospitals and are extremely difficult to treat as they are resistant to many antibiotics. Many emerging diseases are zoonotic - an animal reservoir incubates the body with only intermittent transmission in human populations.

Track 9: Antibiotics and Antimicrobial Use

Antibiotics are one of the most important therapeutic discoveries in the history of medicine. They have revolutionized the way we treat patients with infections and help reduce mortality and morbidity. Unfortunately, antibiotics are more likely to be misused. They are often unnecessarily prescribed for viral infections, against which they have no effect. Not only antibiotics, other antivirals and antimicrobials are losing their effectiveness due to their irrational use and causing antimicrobial resistance.

Track 10: Microbial pathogenesis and Antimicrobial Resistance

Microbial Pathogenesis reviews about the molecular and cellular mechanisms of infectious diseases. It covers microbiology, host-pathogen interaction and immunology related to infectious agents. Antimicrobial resistance refers to the natural ability of microbes to evolve genetically to counter medications. The misuse of antibiotics leads to the appearance and selection of resistant bacteria. Now the whole world is facing situation where infected patients cannot be treated effectively because the responsible bacterium is totally resistant to the antibiotics available.

Track 11: Infection Prevention and Control

Infection control concerns the prevention of nosocomial and healthcare acquired infections. These infections are often caused by violations of infection control practices and procedures, contaminated and non-sterile surfaces or by sick hospital staff. It requires an integrated approach, a follow-up program that includes the following key elements as limiting the transmission of organisms between patients in direct patient care through hand washing and the use of appropriate gloves and aseptic practice, strategies for isolation, sterilization and disinfection practices, and nutrition and immunization, limiting the risk of endogenous infections minimizing invasive procedures and promoting optimal use of antimicrobials, infection surveillance, Identification and control of epidemics, prevention of infection among staff members, strengthening of patient care practices and continuous training of staff.

Track 12: Epidemiology and Public Health

Epidemiology is the "who, what, when, and where" of infectious diseases. The agents are transmitted through the air, food, insects, and some spread through person to person. Some agents occur worldwide, and others only in certain geographic areas or ecological circumstances. Every life form built its own profile vital. It is essential to discover the emergence of "new" diseases. Epidemiology helps develop the methodology to be used in clinical research studies, and  to a lesser extent, basic research in the biological sciences. Epidemiological studies involve an introduction, all the historical background, sources of surveillance data, laboratory diagnosis, the biological characteristics of the organism, mechanisms and routes of transmission, pathogenesis and immunity response the host, and finally the prevention, control and treatment. Epidemiologists with the help of the study design, data collection and statistical analysis of data, as well as the interpretation and dissemination of results that include peer review and the occasional systematic review. In this, they help implement and evaluate interventions at individual and community level
 

Track 13: Opportunistic Infections

Opportunistic infection is an infection caused by pathogens like bacteria, viruses, fungi or protozoa that take advantage of an opportunity that is not normally available such as a host with a weakened immune system, a modified micro biota (like disturbed Intestinal flora) or violated the integumentary barriers. Many of these pathogens do not cause disease in a healthy host that is a normal immune system. However, a compromised immune system, penetrating injury or lack of competition from normal commensals presents an opportunity for the pathogen to infect.

Track 14: Therapeutic Approaches

Nosocomial infections are a major challenge for patient safety. Empirical antibiotic therapy should be based on thorough clinical evaluation and local epidemiological data on potential pathogens and susceptibility to antibiotics. The chosen therapy must be effective, limit the toxicity and be the narrowest spectrum possible. The choice of parenteral, oral or topical antibiotic formulations is made on the basis of clinical presentation (site and severity of infection).

Track 15: Vaccines and Immunization

A vaccine is a biological product that provides active acquired immunity to a particular disease

A vaccination is the injection of a killed or weakened organism that produces immunity against particular organism in the body.

Immunization is the process by which a person or animal is protected from disease. Vaccines cause immunization, and there are also some diseases that cause immunization after a person recovers from the disease.

Track 16: Diagnostic Mirobiology and Bioterrorism

Diagnostic microbiology plays a key role in individual and community health. Clinical microbiology laboratory which is a part of diagnostic microbiology plays essential role for the welfare of our people to analyse samples from patients and collecting data that allow the correct diagnosis to be made for victims of infectious diseases. They are sentinel events for bioterrorism and natural outbreaks of infection that threaten public health of the communities they serve. These laboratories provide vital information which guides the choice of antimicrobial therapy right for patients to infections that can be treated. They are the first to recognize the emergence of resistance to commonly used antimicrobial drugs. People working in clinical microbiology laboratories are highly trained professionals who make countless decisions every day that save lives and benefit the patients and at risk in our society.

Track 17: Occupational Health hazards and safety

Biological agents, including microorganisms and toxins produced by living organisms, can cause health problems in workers. Influenza is an example of a biohazard which affects a broad population of workers. Occupational illness results from exposure in a workplace to a physical, chemical or biological agent to the extent that the normal physiological mechanisms are affected and the health of the worker is impaired.

Track 18: Environmental Microbiology and Bioterrorism

Microbes are all over the world and in every possible environment. For example into the soil, one gram contains billions of microbes and all their related activities. Imagine the challenge to explore all the main groups of microbes found in each of the biomes of the earth given the scale of their immense diversity. So imagine the challenge of developing strategies to exploit and manipulate their activities. This is what environmental microbiology is about.

Track 19: Medical Microbiology

Medical microbiology deals with the body's response to the invasion of microorganisms. Bacteriology, virology, mycology, parasitology are the main areas of concern in medical microbiology. Microbial generations are intelligent enough to cause a change in their resistance patterns, paving the way for the development of new strategies and new trends in the fight against microbial infections. There has been a tremendous change in diagnostic methods and tools from the nucleic acid framework to circulate biomarker studies.

Track 20: Pharmaceutical Microbiology

Pharmaceutical Microbiology includes research and development of antibiotic resistance, anti-infective agents, the use of microorganisms to detect carcinogenic activity and mutagenic in scheduled drugs, as well as the use of microorganisms in the making pharmaceutical products such as human growth hormone and insulin. It also focuses on the safety of medicines and also determines how a product will react in cases of contamination.

Track 21: Clinical Studies and Case Reports

Clinical studies help invent new treatment methods that help provide effective treatment. Case reports on infectious diseases include research, biology, epidemiology and clinical aspects of all diseases related to infection.

Track 22: Health Care Professionals and Infections Specialists Meeting

Health professionals and specialists in the field of microbial infection control, prevention and treatment can exhibit their products and make presentations on their products and research that should be useful in research work, business development and marketing.

Track 23: Entrepreneurs Investment Meet

A platform designed to connect Entrepreneurs, Investors and Proposers worldwide. It aims to create and facilitate the most optimized and viable meeting place to engage people in global business discussions, evaluating and executing promising business ideas. An investor might be able to find the best potential investment opportunities globally, which provide a good return on investment. For entrepreneurs, it would be a great place to find investors and appropriate partners to start and expand their business. Thus, it is an ideal place to connect entrepreneurs, business owners, start-up companies and established companies with domestic or international investors, corporate investors and potential business partners.

Track 24:  Global trends in Nosocomial and Healthcare Acquired Infections

The global hospital acquired infections testing market is poised to grow at a compound annual growth rate (CAGR) of around 19.1% over the next decade to reach approximately $2.75 billion by 2025.
The global market for selected healthcare-acquired infection (HAI) treatments was valued at nearly $15.2 billion in 2014. This market is expected to increase from nearly $17.1 billion in 2015 to $23 billion by 2020, with a compound annual growth rate (CAGR) of 6.1% from 2015 to 2020.
Estimated cost of treating resistant infections in U.S. Health care system is about $21 billion to $34 billion annually.

Global Market Research Report

Global Market Research Report

The Global Nosocomial Infection Control Market is projected to reach USD 53.78 billion by 2021 and is growing at a CAGR of 8.3% during the forecast period from 2017 to 2021. Hospital acquired infections are also called as nosocomial infections and are acquired in hospitals and other healthcare facilities. These infections can occur up to 48 hours after hospital admission or up to 3 days after discharge or up to 30 days after an operation or in a healthcare facility, when the patient was admitted for reasons other than infection.

In the geographical analysis, North America is the leading market for hospital acquired bacterial infections treatment and testing market. Due to stringent hospital regulatory policies and increased government initiatives to prevent and control various hospital-acquired infections, this region is able to maintain its dominant position across the world. Europe closely follows North America is terms of growth, due to increasing incidence of hospital-acquired infections. According to the Health Protection Agency (HPA) approximately of patients in hospitals in England acquire some form of bacterial infection during their hospital stay. However, other regions such as South East Asia, Middle East and Latin America are expected to be the promising markets in the near future. Owing to the rising disposable income among population, increasing incidence of bacterial infections and developing healthcare infrastructure, these regions are expected to be the potential market in the near future.